BlueRock and Senti Collaborate
Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.
About Andrew Humphreys
This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
Entries by Andrew Humphreys
U.S. intelligence community acknowledges two theories of coronavirus origin
The U.S. intelligence community on May 27 acknowledged its agencies had two theories on where the coronavirus originated, with two agencies believing it emerged naturally from human contact with infected animals and a third embracing a possible laboratory accident as the source of the Covid-19 pandemic.
FDA Approves Biohaven’s Nurtec ODT
The U.S. Food and Drug Administration approved Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. Nurtec ODT is indicated for adult patients with episodic migraine, e.g. those who experience less than 15 headache days per month.
FDA Approves Heavy Menstrual Bleeding Drug
The U.S. Food and Drug Administration granted approval to Myfembree, Myovant Sciences and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Patients receiving the therapy under the newly approved indication can take the medicine for up to 24 months.
Eli Lilly receives DoJ subpoena
Eli Lilly said on May 27 the company received a subpoena from the U.S. Department of Justice related to the New Jersey plant that makes the Covid-19 treatment, bamlanivimab.
Russian court rejects Gilead’s lawsuit over Covid-19 drug remdesivir
Russia’s Supreme Court on May 27 rejected a lawsuit from Gilead Sciences that challenged a Russian government decision to let a Russian firm develop and market the anti-Covid-19 drug remdesivir without the U.S. company ‘s consent.
Biden orders review of Covid origins as lab leak theory debated
President Joe Biden ordered aides to find answers to the origin of the virus that causes Covid-19, saying on May 26 that U.S. intelligence agencies are pursuing rival theories potentially including the possibility of a laboratory accident in China.
Sanofi, GSK kick off Phase III trial for Covid-19 shot
France’s Sanofi and Britain’s GlaxoSmithKline launched a late-stage human trial for a recombinant Covid-19 vaccine candidate on May 27 which they hope to get approved by the end of 2021.
Sinopharm’s two Covid-19 shots effective, study says
Two Covid-19 vaccines from China’s Sinopharm showed more than 70 percent efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public.
U.S. FDA gives emergency use approval for GSK-Vir Covid-19 antibody drug
The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
